Thompson Peter A. 4
4 · Corvus Pharmaceuticals, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Corvus (CRVS) 10% Owner Peter A. Thompson Receives 15,000-Share Award
What Happened Peter A. Thompson, listed as a 10% owner of Corvus Pharmaceuticals (CRVS), received a derivative award for 15,000 shares on June 11, 2026. The award was granted at $0.00 (no cash paid) and is reported as an award/derivative (Form 4 code "A"). This was a grant of rights to acquire shares in the future, not a sale or open-market purchase.
Key Details
- Transaction date: 2026-06-11; filing date: 2026-06-15 (filed within the required two business days).
- Instrument: derivative award/option for 15,000 shares reported at $0.00.
- Shares owned after transaction: not specified in the filing; reporting person disclaims beneficial ownership per footnote (see below).
- Footnote F1: Award vests and becomes exercisable 100% on the earlier of (i) the first anniversary of the grant or (ii) the 2027 Annual Meeting, subject to continued service.
- Footnote F2: Thompson is obligated to transfer any securities or economic benefit from this award to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC for the benefit of OrbiMed Private Investments V, LP; he disclaims beneficial ownership except for any pecuniary interest.
Context This filing reports a grant of an option/award (a derivative), not an immediate exercise or sale — no shares were sold and no cash was exchanged at grant. The footnotes indicate the award is intended to benefit an institutional investor (OrbiMed Private Investments V, LP), and the reporting person disclaims beneficial ownership. Grants like this are commonly part of compensation or investment arrangements and do not, by themselves, indicate immediate buying or selling in the market.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-11+15,000→ 15,000 totalExercise: $11.60Exp: 2036-06-11→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- [F2]Pursuant to an agreement with OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.